Neurodegeneration In The Nigrostriatal Dopamine System (DaTscan / VMAT2 PET) And Central Dogma Process (Page 1154)
Neurodegeneration in the nigrostriatal dopamine system — Parkinson’s disease (Takeda slide)
- DaTscan ([123I]β-CIT) SPECT
- Widely available, used clinically
- History of use in clinical PD trials
- Qualified as a patient enrichment biomarker by the EMA
- Substantial natural history data available (PPMI)
- VMAT2 ([18F]AV-133) PET
- Higher quality images than DaTscan
- Preliminary data in PPMI
- May provide increased sensitivity to DA neuron loss and longitudinal change
- Takeda is helping to fund PPMI sub-study to expand longitudinal data set
- Longitudinal characteristics of DaTscan SPECT and [18F]AV-133 PET
- [18F]AV-133 has lower variance across subjects in one year percent change in striatal signal, which translates to a greater statistical effect size and reduced sample sizes to detect an equivalent slowing following treatment
- The sample sizes shown here are calculated for a 50% slowing of dopamine signal decrease over 12 months
- These calculations are based on N=345 subjects for DaTscan but only N=17 for [18F]AV-133
clv) John Siebyl on DaT and VMAT2 in PPMI
a. Early PD imaging markers: AV-133/DaTscan (20210824)
[11C]DTBZ
- Human PET studies have predominantly utilized [11C]DTBZ, (Figure 2) a purposefully designed high affinity metabolite of tetrabenazine, with increasing use in recent years of the molecule [18F] ]fluoropropyl-dihydrotetrabenazine ( AV-133) (Figure 2). (Kilbourn 2021, Biomedicines 2021, 9, 108)
VIVIKI
techniques
| Example | ||
|---|---|---|
| Manual | 내가 부평에서 한 것: | structures of interest were outlined manually at baseline and again at f/u |
| Semiautomated + automated | boundary shift integral (BSI) technique | semi-automated segmentation of the baseline region → automatic calculation of the in |
| (fully) automated | Voxel-based morphometry |
VPS35 (PARK17)
Whole Exome Sequencing
| (Bustos, 2020 #2389) | (i) IPDGC5, comprising 1,042 PD cases and 452 controls, (ii) PPMI, with 383 PD cases and 144 controls |
| (Gaare, 2020 #2390) |
(i) The Norwegian WES cohort comprised 191 patients with PD from the Norwegian ParkWest study [10] and 219 controls ii) PPMI) [19]: WES data was available from 640 individuals (459 cases and 181 controls). |
References
3333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333
[MOLECULAR BIOLOGY]
Central Dogma Process
| location | • | ||||||
|---|---|---|---|---|---|---|---|
| ↓ | Transcription | Nucleus |
DNA → pre-Mrna 시작: A polymerase attaches to promoter of DNA so it can know where to start
| ||||
| RNA splicing (=Alternative splicing, or alternative RNA splicing, or differential splicing) | Nucleus |
DNA → Pre-mRNA → mRNA - Definition
For those eukaryotic genes that contain introns, splicing is usually required in order to create an mRNA molecule that can be translated into protein. For many eukaryotic introns, splicing is carried out in a series of reactions which are catalyzed by the spliceosome, a complex of small nuclear ribonucleo proteins (snRNPs).
| |||||
| Translation, Synthesis | cytoplasm |
Ribosome 이 mRNA로부터 polypeptides 를 synthesize (outside nucleus):
| |||||
| ER | Cleaved → protein folding 시작 | ||||||
| Protein folding by chaperones | ER |
| |||||
| Quality control | ER |
|
DNA replication (DNA → DNA)
DNA Polymerase
Uncertain Spans
| location | transcription | uncertainty |
|---|---|---|
| References row | repeated 3 characters | The References section is followed by a long band of 3 characters in the source — appears to be a placeholder line with no other text in this capture; reproduced as visible. |
| VIVIKI techniques table | header VIVIKI | The header reads as VIVIKI in this capture; the V-shaped first letter is small but matches the body_full pixel pattern. |
| Whole Exome Sequencing row 2 | trailing (459 cases and 181 controls). | The right edge of the table is cut at the photo border; the visible numeric cells are reproduced as printed. |
| RNA splicing diagram cell | example labels GGGGCC repeat / CGG triplet / CCG triplet / GAA triplet / CAG triplet and the ALS / Friedreich ataxia / HD / SBMA / SCA1-3,6,7,17 / DM1 example lists | The example labels accompany the alternative-splicing schematic and read as printed; some are listed under RAN translation disease and translation disease headers. |
| Quality control 4. row | aggresome 형성 (Retrograde axonal transport시 protein을 끌고가서 MTOC근처에) | The trailing parenthetical Korean note is small and ends close to the photo edge; the reading reproduces the visible characters. |